Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.68M Buy
69,662
+712
+1% +$18.6K 0.02% 126
2026
Q1
$1.94M Buy
68,950
+1,279
+2% +$34.1K 0.02% 123
2025
Q4
$1.69M Sell
67,671
-3,155
-4% -$79.6K 0.02% 125
2025
Q3
$1.8M Sell
70,826
-32,357
-31% -$799K 0.02% 125
2025
Q2
$2.5M Buy
103,183
+3,157
+3% +$73.6K 0.03% 107
2025
Q1
$2.53M Sell
100,026
-677
-0.7% -$17.7K 0.03% 106
2024
Q4
$2.67M Buy
100,703
+6,888
+7% +$187K 0.03% 108
2024
Q3
$2.72M Buy
93,815
+36,370
+63% +$1.06M 0.04% 103
2024
Q2
$1.61M Buy
57,445
+300
+0.5% +$8.26K 0.03% 121
2024
Q1
$1.59M Buy
57,145
+6,979
+14% +$194K 0.03% 119
2023
Q4
$1.44M Sell
50,166
-255
-0.5% -$7.71K 0.03% 122
2023
Q3
$1.67M Buy
50,421
+1,850
+4% +$65.4K 0.03% 109
2023
Q2
$1.78M Buy
48,571
+209
+0.4% +$8.13K 0.04% 106
2023
Q1
$1.97M Sell
48,362
-2,550
-5% -$110K 0.04% 99
2022
Q4
$2.61M Hold
50,912
0.04% 84
2022
Q3
$2.23M Sell
50,912
-654
-1% -$31.8K 0.04% 89
2022
Q2
$2.7M Sell
51,566
-1,940
-4% -$98.9K 0.06% 84
2022
Q1
$2.77M Hold
53,506
0.06% 97
2021
Q4
$3.16M Buy
53,506
+189
+0.4% +$9.36K 0.07% 89
2021
Q3
$2.29M Sell
53,317
-1,100
-2% -$48.7K 0.05% 108
2021
Q2
$2.13M Sell
54,417
-3,268
-6% -$127K 0.04% 120
2021
Q1
$2.09M Buy
57,685
+2,253
+4% +$80K 0.05% 118
2020
Q4
$2.04M Sell
55,432
-11,030
-17% -$405K 0.07% 111
2020
Q3
$2.31M Buy
66,462
+1,660
+3% +$58.2K 0.09% 100
2020
Q2
$2.01M Sell
64,802
-3,945
-6% -$134K 0.07% 103
2020
Q1
$2.13M Buy
68,747
+1,257
+2% +$42.8K 0.09% 84
2019
Q4
$2.51M Buy
67,490
+2,064
+3% +$73.5K 0.07% 88
2019
Q3
$2.23M Sell
65,426
-3,475
-5% -$126K 0.07% 102
2019
Q2
$2.83M Sell
68,901
-1,199
-2% -$47.6K 0.08% 93
2019
Q1
$2.83M Buy
+70,100
New +$2.81M 0.08% 94

Other funds holding PFE

Murray Stahl's PFE Position: Q2 2026 in Review

Murray Stahl increased its Pfizer (PFE) stake by 1% in Q2 2026, buying an estimated $18.6K and bringing the position to 69,662 shares worth $1.68M. The position accounts for 0.02% of the portfolio, ranked #126.

Murray Stahl first reported a position in PFE in Q1 2019 and has held it in 30 quarters since. The position peaked at $3.16M in Q4 2021. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Murray Stahl held 69,662 shares of Pfizer worth $1.68M as of Q2 2026.
  • Murray Stahl bought 712 Pfizer shares in Q2 2026, an estimated $18.6K.
  • Pfizer made up 0.02% of Murray Stahl's portfolio in Q2 2026, its #126 holding.
  • Murray Stahl first reported a position in Pfizer in Q1 2019 and has held it in 30 quarters since.
  • Murray Stahl's Pfizer position peaked at $3.16M in Q4 2021.
  • 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Horizon Kinetics Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.